ILIAS accelerates the world’s first clinical trial of a new drug based on exosomes

ILIAS Biologics will submit an IND application to Australian authorities in February this year for the world’s first Phase 1 clinical trial of its exosome-based anti-inflammatory drug candidate (ILB-202), the co-CEO says of the company, Choi Chulhee.

After the phase 1 trial, a phase 2 clinical trial will follow in the United States late this year or early next year.

“This year will be the first year of the largest exosome clinical research in our company’s history. As the world’s leading exosome engineering company together with Britain’s Evox Therapeutics and US Codiak Biosciences, we will demonstrate the efficacy of exosome therapeutics and discuss potential investments from big pharma,” Choi said during a briefing. recent interview with Maeil Business Newspaper.

Exosomes are extracellular vesicles with a diameter of 50 to 200 nanometers in the human body. They were thought to be by-products of cellular metabolism, but today they are attracting the attention of the pharmaceutical industry as potential therapeutics because they may play a role in cell-to-cell communication.

Exosomes are likened to messengers or couriers because therapeutic agents can be loaded into them for precise delivery to target areas without causing side effects on other parts of the body.

Exosomes can serve as potential diagnostic biomarkers for diseases or therapeutic compounds because they transport proteins, nucleic acids, lipids and metabolites. However, potential therapeutics are still in the early stages of development.

ILIAS Biologics has the fourth most advanced step in exosome engineering. Unlike previous generations, fourth-generation exosome technology enables active loading of large therapeutic cargo proteins into the lumen of exosomes and delivery of payload proteins to a desired site in the cytoplasm, Choi explained.

In recognition of its groundbreaking technology, the company received the “Cytiva Korea CEO Award” in 2019.

“There is no commercially available treatment in the exosome market yet, but as was the case with Moderna with the mRNA platform technology, we will see an exosome engineering company whose the enterprise value could reach $100 billion to $200 billion within 10 years,” said Ham Taejin, Co-CEO of ILIAS Biologics.

By Kim Si-gyun and Minu Kim

[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]

About Cecil Cobb

Check Also

Graphic Novel Review: “Tristan Strong Punches a Hole in the Sky”

Kwame Mbalia’s dazzling story of Tristan Strong returns to book format in a stunning visual …